(CercleFinance.com) – The biotechnology company Celyad had cash and cash equivalents of 14.4 million euros at the end of the first half, against 12 million euros a year earlier.
This specialist in chimeric antigen receptor T cell therapies (CAR T) against cancer says it recorded a net loss of 14.1 million euros in the first half of 2022, compared with a loss of 14.9 million euros. euros a year earlier.
For the record, the US FDA recently lifted the clinical hold of CYAD-101, one of its allogeneic CAR T product candidates, for metastatic colorectal cancer.
Data on CYAD-211, the lead allogeneic product candidate for the treatment of relapsed/refractory multiple myeloma, are also expected in the second half of 2022.
Celyad shares, listed on Euronext in Paris and Brussels, rose 3.1% on Friday following this publication.